×
About 32,476 results
ACG Clinical Guideline: Hereditary Hemochromatosis
https://journals.lww.com/ajg/Fulltext/2019/08000/ACG_Clinical_Guideline__Hereditary_Hemochromatosis.11.aspx
Kowdley, K. et. al.

Aug 1st, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic testing for HH has made possible confirmation of the diagnosis for most patients. Several genotype-phenotype correlation studies have clarified the diffe...

Updates to the 2019 Standards of Medical Care in Diabetes Issued Today by the American Diabetes Association
http://www.diabetes.org/newsroom/press-releases/2019/updates-standards-medical-care.html

Jul 30th, 2019 - The American Diabetes Association® (ADA) issued important updates to the 2019 Standards of Medical Care in Diabetes (Standards of Care) today, in annotations as the Living Standards of Care, with the changes focusing on new metrics for continuous glucose monitoring (CGM) utilization and new medication options and recommendations for youth and adults with type 2 diabetes. The updates were inform...

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study
https://annals.org/aim/article-abstract/2739786/sodium-glucose-cotransporter-2-inhibitors-risk-severe-urinary-tract-infections
Annals of Internal Medicine;

Jul 29th, 2019 - Background: Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium–glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings. Objective: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like...

FDA approves Feraccru® with a broad label of treating iron deficiency in adults
https://www.shieldtherapeutics.com/wp-content/uploads/2019/07/STX-Feraccru-FDA-approval-26.07.19.pdf

Jul 25th, 2019 - Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product Feraccru® / Accrufer® for the treatment of iron deficiency in adults. With this broad label approval Accrufer® (as the product will be marketed in the USA) has taken a big step towar...

New Approaches Improve Diagnosis, Prediction of Type 2 Diabetes
https://www.patientcareonline.com/t2-diabetes/new-approaches-improve-diagnosis-prediction-type-2-diabetes

Jul 25th, 2019 - The accuracy of diagnosing and predicting type 2 diabetes mellitus (T2DM) and prediabetes could be improved by applying multiple or alternative measures, according to studies presented at the American Diabetes Association (ADA) Scientific Sessions meeting in San Francisco, CA, in June. Joon Ha, PhD, Laboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Disea...

AHA's "Life's Simple 7" Reduces Heart Failure Risk
https://www.patientcareonline.com/cardiovascular-disease/ahas-lifes-simple-7-reduces-heart-failure-risk

Jul 24th, 2019 - The incidence of congestive heart failure (HF) was reduced by 47% in a group of individuals adhering to a combination of healthy lifestyle practices; among individuals who adhered to an “ideal” combination of those practices, HF was reduced by 55%. In a recent study that analyzed the impact of the American Heart Association’s (AHA) Life’s Simple 7 (LS7) healthy behaviors on HF risk reduction, t...

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally

Jul 23rd, 2019 - The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY) announced today. BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind. It is compact, portable and ready to ...

Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke
https://jamanetwork.com/journals/jama/article-abstract/2738553
JAMA

Jul 22nd, 2019 - Question Does intensive glucose control improve functional outcome in patients with hyperglycemic acute ischemic stroke? Findings This randomized clinical trial included 1151 adults who received either intensive treatment of hyperglycemia (target blood glucose concentration of 80-130 mg/dL) or standard treatment of hyperglycemia (target glucose concentration of 80-179 mg/dL). The proportio...

Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map
https://annals.org/aim/article-abstract/2737825/effects-nutritional-supplements-dietary-interventions-cardiovascular-outcomes-umbrella-review-evidence
Annals of Internal Medicine; Khan, S. et. al.

Jul 8th, 2019 - Background: The role of nutritional supplements and dietary interventions in preventing mortality and cardiovascular disease (CVD) outcomes is unclear. Purpose: To examine evidence about the effects of nutritional supplements and dietary interventions on mortality and cardiovascular outcomes in adults. Data Sources: PubMed, CINAHL, and the Cochrane Library from inception until March 20...

Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study
https://www.bmj.com/content/366/bmj.l4414
BMJ Sabia, S. et. al.

Jun 11th, 2019 - Objectives To examine the association between the Life Simple 7 cardiovascular health score at age 50 and incidence of dementia. Design Prospective cohort study. Setting Civil service departments in London (Whitehall II study; study inception 1985-88). Participants 7899 participants with data on the cardiovascular health score at age 50. Exposures The cardiovascular health score inc...

Vitamin D Supplementation and Prevention of Type 2 Diabetes
https://www.nejm.org/doi/10.1056/NEJMoa1900906
New England Journal of Medicine; Pittas. A., et al

Jun 6th, 2019 - Observational studies support an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes. However, whether vitamin D supplementation lowers the risk of diabetes is unknown. METHODS We randomly assigned adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose level 2 hou...

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
http://care.diabetesjournals.org/content/42/6/1147
Diabetes Care; Danne, T. et. al.

May 31st, 2019 - Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolut...

Metformin | PubChem
https://pubchem.ncbi.nlm.nih.gov/compound/metformin

May 10th, 2019 - A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification.

Pediatric Systemic Lupus Erythematosus Workup
https://emedicine.medscape.com/article/1008066-workup

Apr 26th, 2019 - The initial laboratory evaluation should include a complete blood count (CBC) with platelets and reticulocyte count; a complete chemistry panel to evaluate electrolytes, liver, and kidney function; urine analysis; and a measure of acute phase reactants (eg, erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]).

Reprogramming Cells to Make Insulin
https://academic.oup.com/jes/article/3/6/1214/5476582
Journal of Endocrine Society;

Apr 23rd, 2019 - Type 1 diabetes is a disease characterized by the destruction of insulin-secreting β-cells in the pancreas. Individuals are treated for this disease with lifelong insulin replacement. However, one attractive treatment possibility is to reprogram an individual’s endogenous cells to acquire the ability to secrete insulin, essentially replacing destroyed β-cells. Herein, we review the literature o...

A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults
https://academic.oup.com/jn/article-abstract/149/6/968/5475972?redirectedFrom=fulltext
The Journal of Nutrition; Mejia, S. et. al.

Apr 21st, 2019 - Certain plant foods (nuts and soy protein) and food components (viscous fibers and plant sterols) have been permitted by the FDA to carry a heart health claim based on their cholesterol-lowering ability. The FDA is currently considering revoking the heart health claim for soy protein due to a perceived lack of consistent LDL cholesterol reduction in randomized controlled trials.

Lupus Erythematosus - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK535405/

Apr 19th, 2019 - The acute form of systemic lupus erythematosus (SLE) differs from the chronic form. It disseminates differently, and it is highly fatal. Kaposi was the first in recognizing SLE in 1872, and then Pernet described it in 1908. Before that time SLE was considered to be a non-fatal disfiguring skin disease. It is now to be considered a chronic inflammatory disease characterized by a course of altern...

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
https://www.nejm.org/doi/full/10.1056/NEJMoa1811744?query=recirc_curatedRelated_article

Apr 13th, 2019 - Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.